# FORM 7

# MONTHLY PROGRESS REPORT

Name of Listed Issuer: <u>Beyond Medical Technologies Inc.</u> (the "**Issuer**" or the "**Company**").

Trading Symbol: DOCT

Number of Outstanding Listed Securities: 78,716,341

Date: April 7, 2021

#### **Report on Business**

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

Beyond Medical Technologies Inc. (the "Company"), through its whollyowned subsidiary of Micron Technologies Inc. has been manufacturing Class 1 Medical Devices pursuant to its Medical Device Establishment License from Health Canada and medical device registration with U.S. Food and Drug Administration.

The Company continues to manufacture 3-ply surgical face masks (Model F2100) and face mask filters (Model F98). The Company's N95 (Model 8800) respirators have passed the preliminary testing required for NIOSH approval. The company has purchased raw materials to begin manufacturing of it's N95 respirators.

2. Provide a general overview and discussion of the activities of management.

The Company has been manufacturing personal protective equipment (PPE) and seeking trial partners for the Pharmavore waste digester in order to advance the product to commercialization.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or strategic plan oil and gas or other reports required under Ontario securities law.

The Company is starting preliminary production of N95 respirators. This product will be available for sale as a non-medical device in April. The company is developing it's e-commerce platform to start accepting bitcoin as a form of payment.

4. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

#### None.

5. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

### None.

6. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the dispositions was to a Related Person of the Issuer and provide details of the relationship.

# None.

7. Describe the acquisition of new customers or loss of customers.

### None.

8. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

# None.

9. Report on any employee hiring's, terminations or lay-offs with details of anticipated length of lay-offs.

# Company-wide, there were no new hires and one lay-off.

10. Report on any labour disputes and resolutions of those disputes if applicable.

# None.

11. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

# None.

12. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

# None.

13. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds
Common Shares and Warrants	11,619,500	Issued 11,619,500 Units at a price of \$0.125 for gross proceeds of \$1,452,437.50. Each Unit consists of one common share in the capital of the company and one share purchase warrant. Each warrant is exercisable to purchase one additional share at a price of \$0.20 cents per warrant share until March 11, 2023.	For general corporate purposes.
Common Shares	205,000	Issued 205,000 common shares as a result of the exercise of 205,000 warrants at a price of \$0.10 for gross proceeds of \$20,500.00.	For general current purposes.

14. Provide details of any loans to or by Related Persons.

### None.

15. Provide details of any changes in directors, officers or committee members.

#### None.

16. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The Issuer's business involves certain risks and uncertainties that are inherent to the Issuer's industry. Please to the "Risks Related To The Business" section of the Issuer's management discussion and analysis for the year ended December 31, 2019, which is available on SEDAR at www.sedar.com.

#### **Certificate Of Compliance**

The undersigned hereby certifies that:

- 1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
- 2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
- 3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
- 4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: <u>April 7, 2021</u>

<u>Kal Malhi</u> Name of Director or Senior Officer

<u>"Kal Malhi"</u> Signature

Interim President and CEO Official Capacity

<i>Issuer Details</i> Name of Issuer	For Month End	Date of Report YY/MM/D		
Micron Waste Technologies Inc.	March 31, 2021	2021/04/07		
Issuer Address Suite 915 – 700 West Pender Street				
City/Province/Postal Code	Issuer Fax No.	Issuer Telephone No.		
Vancouver, BC V6C 1G8	NA	(604) 805-4602		
Contact Name	Contact Position	Contact Telephone No.		
Kal Malhi	Interim President and CEO	(604)805-4602		
Contact Email Address info@micronwaste.com	Web Site Address www.micronwaste.com			